Literature DB >> 33428144

Feasibility of MRI Radiomics for Predicting KRAS Mutation in Rectal Cancer.

Xiao-Fang Quo1,2, Wen-Qian Yang3, Qian Yang2, Zi-Long Yuan2, Yu-Lin Liu2, Xiao-Hui Niu3, Hai-Bo Xu4.   

Abstract

The mutation status of KRAS is a significant biomarker in the prognosis of rectal cancer. This study investigated the feasibility of MRI-based radiomics in predicting the mutation status of KRAS with a composite index which could be an important criterion for KRAS mutation in clinical practice. In this retrospective study, a total of 127 patients with rectal cancer were enrolled. The 3D Slicer was used to extract the radiomics features from the MRI images, and sparse support vector machine (SVM) with linear kernel was applied for feature reduction. The radiomics classifier for predicting the KRAS status was then constructed by Linear Discriminant Analysis (LDA) and its performance was evaluated. The composite index was determined with LDA model. Out of 127 rectal cancer subjects, there were 44 KRAS mutation cases and 83 wild cases. A total of 104 radiomics features were extracted, 54 features were filtered by linear SVM with L1-norm regularization and 6 features that had no significant correlations within them were finally selected. The radiomics classifier constructed using the 6 features featured an AUC value of 0.669 (specificity: 0.506; sensitivity: 0.773) with LDA. Furthermore, the composite index (Radscore) had statistically significant difference between the KRAS mutation and wild groups. It is suggested that the MRI-based radiomics has the potential in predicting the KRAS status in patients with rectal cancer, which may enhance the diagnostic value of MRI in rectal cancer.

Entities:  

Keywords:  KRAS mutation; MRI; radiomics; rectal cancer

Year:  2021        PMID: 33428144     DOI: 10.1007/s11596-020-2298-6

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  21 in total

1.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Authors:  Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Briant Fruth; Jeffrey A Meyerhardt; Deborah Schrag; Claire Greene; Bert H O'Neil; James Norman Atkins; Scott Berry; Blase N Polite; Eileen M O'Reilly; Richard M Goldberg; Howard S Hochster; Richard L Schilsky; Monica M Bertagnolli; Anthony B El-Khoueiry; Peter Watson; Al B Benson; Daniel L Mulkerin; Robert J Mayer; Charles Blanke
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

2.  Radiomics: a new application from established techniques.

Authors:  Vishwa Parekh; Michael A Jacobs
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-03-31

3.  Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Authors:  Zhenyu Liu; Xiao-Yan Zhang; Yan-Jie Shi; Lin Wang; Hai-Tao Zhu; Zhenchao Tang; Shuo Wang; Xiao-Ting Li; Jie Tian; Ying-Shi Sun
Journal:  Clin Cancer Res       Date:  2017-09-22       Impact factor: 12.531

Review 4.  Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology.

Authors:  E J Limkin; R Sun; L Dercle; E I Zacharaki; C Robert; S Reuzé; A Schernberg; N Paragios; E Deutsch; C Ferté
Journal:  Ann Oncol       Date:  2017-06-01       Impact factor: 32.976

5.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

Authors:  Sebastian Stintzing; Dominik P Modest; Lisa Rossius; Markus M Lerch; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Swantje Held; Clemens Giessen-Jung; Markus Moehler; Andreas Jagenburg; Thomas Kirchner; Andreas Jung; Volker Heinemann
Journal:  Lancet Oncol       Date:  2016-08-27       Impact factor: 41.316

6.  Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival.

Authors:  Francesca Ng; Balaji Ganeshan; Robert Kozarski; Kenneth A Miles; Vicky Goh
Journal:  Radiology       Date:  2012-11-14       Impact factor: 11.105

7.  Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer.

Authors:  Yan-Qi Huang; Chang-Hong Liang; Lan He; Jie Tian; Cui-Shan Liang; Xin Chen; Ze-Lan Ma; Zai-Yi Liu
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

8.  Rectal Cancer: Assessment of Neoadjuvant Chemoradiation Outcome based on Radiomics of Multiparametric MRI.

Authors:  Ke Nie; Liming Shi; Qin Chen; Xi Hu; Salma K Jabbour; Ning Yue; Tianye Niu; Xiaonan Sun
Journal:  Clin Cancer Res       Date:  2016-05-16       Impact factor: 12.531

Review 9.  KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.

Authors:  Ahmad D Siddiqui; Bilal Piperdi
Journal:  Ann Surg Oncol       Date:  2009-11-20       Impact factor: 5.344

10.  Individualized prediction of perineural invasion in colorectal cancer: development and validation of a radiomics prediction model.

Authors:  Yanqi Huang; Lan He; Di Dong; Caiyun Yang; Cuishan Liang; Xin Chen; Zelan Ma; Xiaomei Huang; Su Yao; Changhong Liang; Jie Tian; Zaiyi Liu
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

View more
  1 in total

Review 1.  Emerging applications of radiomics in rectal cancer: State of the art and future perspectives.

Authors:  Min Hou; Ji-Hong Sun
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.